Evaluation of a Blood Biomarker to Try and Distinguish Between the Presence or Absence of Aggressive Prostate Cancer
A Laboratory Study To Evaluate A Blood Biomarker That Can Distinguish Between the Presence Or Absence of Aggressive Prostate Cancer
Sponsor: AdventHealth
Terminated
Business decision to discontinue development of the IsoPSA assay.
A observational or N/A phase clinical study on Prostate Cancer, this trial is terminated or withdrawn. The trial is conducted by AdventHealth and has accumulated 12 data snapshots since 2018. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Terminated
-
Jul 2024 — Sep 2024 [monthly]
Terminated
-
Dec 2021 — Jul 2024 [monthly]
Terminated
-
Jan 2021 — Dec 2021 [monthly]
Terminated
-
Nov 2020 — Jan 2021 [monthly]
Terminated
▶ Show 7 earlier versions
-
May 2020 — Nov 2020 [monthly]
Terminated
-
Mar 2020 — May 2020 [monthly]
Terminated
Status: Recruiting → Terminated
-
Aug 2018 — Mar 2020 [monthly]
Recruiting
Status: Not Yet Recruiting → Recruiting
-
Jun 2018 — Aug 2018 [monthly]
Not Yet Recruiting
-
May 2018 — Jun 2018 [monthly]
Not Yet Recruiting
-
Apr 2018 — May 2018 [monthly]
Not Yet Recruiting
Phase: NA → None
-
Sep 2017 — Apr 2018 [monthly]
Not Yet Recruiting NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- AdventHealth
- Genomic Health®, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .